Crimson Publishers Publish With Us Reprints e-Books Video articles


Gastroenterology Medicine & Research

Nanoparticle (NP) Delivery of Chemotherapy Drugs to Prostate Cancer Patients

Submission: August 08, 2018 ;Published: September 07, 2018

August 17, 2018
Volume1 Issue1


The use of nanoparticles (NPs) for enhanced drug delivery in prostate cancer treatment has been extensively explored in many studies. However, there are serious limitations to nanoparticle delivery of drugs to prostate cancer. It has become increasingly obvious that the physicochemical properties of the nanoparticles dictate the volume of the nanoparticles needed for the drug delivery. The volume of nanoparticle used in turn determines therapeutic efficacy of the drug and the nanoparticle delivery system. In this review, we reflect on the physical chemistry of NP-mediated drug delivery to the target cell/tissue during prostate cancer treatment.

Keywords: Prostate cancer; Patients; Nanoparticles; Delivery system; Therapeutic efficiency; Drug; NP-Mediated drug; Biodegradable copolymers; Physicochemical properties; Moieties; Oligonucleotides; P-glycoprotein; Bio-compatibilities; 3-Bromopyruvate; SC-514; Quercetin; Prostate specific antigen (PSMA)

Abbreviations: NP: Nanoparticles; 3-BPA: 3-Bromopuruvate; PLGA: Poly lactic-co-glycolic Acid; FDA: Food and Drug Administration; EMA: European Medicine Agency; OVA: Ovalbumin; TLR4: Toll like Receptor-4; TAA: Tumor Associated Antigen; RNA: Ribonucleic Acid; CPs: Control Nanoparticles; PSMA: Prostate-Specific Membrane Antigen

Get access to the full text of this article